Lower urinary tract dysfunction in uncommon neurological diseases, Part II: A report of the Neuro-urology Promotion Committee of the International Continence Society

Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER B.V.
Autores
SINHA, S.
WACHTER, S. De
WELK, B.
SAKAKIBARA, R.
VRIJENS, D. M. J.
KONSTANTINIDIS, C.
RAPIDI, C.-A.
MONTEIRO, L. M.
DRAKE, M. J.
Citação
CONTINENCE, v.7, article ID 101043, p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
This is the second manuscript from the Neuro-urology Promotion Committee of the International Continence Society (ICS) discussing uncommon neuro-urological conditions that are not well described in urological literature. Readers are referred to the first document for a more detailed understanding of how neurological disease might affect lower urinary tract function ( https://doi.org/10.1016/j.cont.2022.100022). Eleven conditions are covered. This includes five genetic conditions — Duchene muscular dystrophy, mitochondrial encephalopathy, Down's syndrome, adrenoleukodystrophy and Ochoa's syndrome. Three infection-associated conditions are covered including central nervous system tuberculosis, schistosomal myeloradiculopathy and post-polio syndrome. Three other conditions covered are myasthenia gravis, syringomyelia and the vegetative state. Key aspects and specific recommendations related to clinical practice are summarized in tables. Knowledge of unusual neurological conditions that can affect the lower urinary tract is important for ensuring a timely and precise diagnosis. This document from the ICS, along with Part I published earlier, can serve as a reference for clinicians presented with unusual forms of neurogenic lower urinary tract dysfunction.
Palavras-chave
Neuro-urology, Neurogenic bladder, Neurogenic lower urinary tract dysfunction
URI
https://observatorio.fm.usp.br/handle/OPI/58689
Referências
  1. Gajewski J., Schurch B., Hamid R., Et al., An international continence society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD), Neurourol. Urodyn., (2018)
  2. Welk B., Sakakibara R., Sinha S., Et al., Lower urinary tract dysfunction in uncommon neurological diseases: A report of the neurourology promotion committee of the international continence society, Continence, 1, (2022)
  3. Norwood F.L.M., Harling C., Chinnery P.F., Et al., Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population, Brain, 132, pp. 3175-3186, (2009)
  4. Mercuri E., Bonnemann C.G., Muntoni F., Muscular dystrophies, Lancet, 394, pp. 2025-2038, (2019)
  5. Lionarons J.M., Hoogl G., Hendriksen R.G.F., Et al., Dystrophin is expressed in smooth muscle and afferent nerve fibers in the rat urinary bladder, Muscle Nerve, 60, pp. 202-210, (2019)
  6. MacLeod M., Kelly R., Robb S.A., Et al., Bladder dysfunction in Duchenne muscular dystrophy, Arch. Dis. Child., 88, pp. 347-349, (2003)
  7. Morse C.I., Higham K., Bostock E.L., Et al., Urinary incontinence in men with Duchenne and Becker muscular dystrophy, PLoS One, 15, (2020)
  8. Bertrand L.A., Askeland E.J., Mathews K.D., Et al., Prevalence and bother of patient-reported lower urinary tract symptoms in the muscular dystrophies, J. Pediatr. Urol., 12, pp. 398.e1-398.e4, (2016)
  9. van Wijk E., Messelink B.J., Heijnen L., Et al., Prevalence and psychosocial impact of lower urinary tract symptoms in patients with duchenne muscular dystrophy, Neuromuscul. Disord., 19, pp. 754-758, (2009)
  10. Lionarons J.M., de Groot I.J.M., Fock J.M., Et al., Prevalence of bladder and bowel dysfunction in duchenne muscular dystrophy using the childhood bladder and bowel dysfunction questionnaire, Life (Basel), 11, (2021)
  11. Garg S., Management of scoliosis in patients with duchenne muscular dystrophy and spinal muscular atrophy: A literature review, J. Pediatr. Rehabil. Med., 9, pp. 23-29, (2016)
  12. Mukherjee S., Roy M., Guha G., Et al., Mutation location and cognitive impairment in duchenne muscular dystrophy, J. Neurosci. Rural. Pract., 9, pp. 410-413, (2018)
  13. La Morgia C., Maresca A., Caporali L., Et al., Mitochondrial diseases in adults, J. Int. Med., 287, pp. 592-608, (2020)
  14. Finsterer J., Zarrouk-Mahjoub S., Involvement of the spinal cord in mitochondrial disorders, J. Neurosci. Rural Pract., 9, pp. 245-251, (2018)
  15. Pfeffer G., Gorman G.S., Griffin H., Et al., Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance, Brain, 137, pp. 1323-1336, (2014)
  16. Garcia-Velasco A., Gomez-Escalonilla C., Guerra-Vales J.M., Et al., Intestinal pseudo-obstruction and urinary retention: cardinal features of a mitochondrial DNA-related disease, J. Int. Med., 253, pp. 381-385, (2003)
  17. Weijerman M.E., de Winter J.P., Clinical practice. The care of children with Down syndrome, Eur. J. Pediatr., 169, pp. 1445-1452, (2010)
  18. Glasson E.J., Dye D.E., Bittles A.H., The triple challenges associated with age-related comorbidities in Down syndrome, J. Intellectual. Disabil. Res., 58, pp. 393-398, (2014)
  19. Dykens E.M., Psychiatric and behavioral disorders in persons with Down syndrome, Ment. Retard. Dev. Disabil. Res. Rev., 13, pp. 272-278, (2007)
  20. Ahmed S., Vesico-ureteric reflux in Down's syndrome: poor prognosis, Aust. N. Z. J. Surg., 60, pp. 113-116, (1990)
  21. Kupferman J.C., Druschel C.M., Kupchik G.S., Increased prevalence of renal and urinary tract anomalies in children with Down syndrome, Pediatrics, 124, pp. e615-621, (2009)
  22. Powers M.K., Brown E.T., Hogan R.M., Et al., Trends in toilet training and voiding habits among children with Down Syndrome, J. Urol., 194, pp. 783-787, (2015)
  23. Kitamura A., Kondoh T., Noguchi M., Et al., Assessment of lower urinary tract function in children with Down syndrome, Pediatr. Int., 56, pp. 902-908, (2014)
  24. Bruschini H., Faria N., Garcez E., Et al., Development of bladder control in mentally handicapped children, Int. Braz. J. Urol., 29, pp. 455-458, (2003)
  25. de Carvalho Mrad F.C., de Bessa J., de Rezende Duarte A.M.B., Et al., Prevalence of lower urinary tract symptoms in individuals with Down syndrome, J. Pediatr. Urol., 10, pp. 844-849, (2014)
  26. Chicoine B., Sulo S., Rate of urinary retention in adults with down syndrome: a prospective study, J. Am. Board. Fam. Med., 28, pp. 115-117, (2015)
  27. Lott I.T., Neurological phenotypes for Down syndrome across the life span, Prog. Brain Res., 197, pp. 101-121, (2012)
  28. Turk B.R., Theda C., Fatemi A., Et al., X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies, Int. J. Dev. Neurosci., 80, pp. 52-72, (2020)
  29. Walther M.M., Cutler G.B., Urodynamic abnormalities in two brothers with adrenomyeloneuropathy, World J. Urol., 15, pp. 262-265, (1997)
  30. Sakakibara R., Hattori T., Fukutake T., Et al., Micturitional disturbance in a patient with adrenomyeloneuropathy (AMN), Neurourol. Urodyn., 17, pp. 207-212, (1998)
  31. Silveri M., De Gennaro M., Gatti C., Et al., Voiding dysfunction in x-linked adrenoleukodystrophy: symptom score and urodynamic findings, J. Urol., 171, pp. 2651-2653, (2004)
  32. Corre C.S., Grant N., Sadjadi R., Et al., Beyond gait and balance: urinary and bowel dysfunction in X-linked adrenoleukodystrophy, Orphanet. J. Rare Dis., 16, (2021)
  33. Ochoa B., Can a congenital dysfunctional bladder be diagnosed from a smile? The Ochoa syndrome updated, Pediatr. Nephrol., 19, pp. 6-12, (2004)
  34. Osorio S., Rivillas N.D., Martinez J.A., Urofacial (ochoa) syndrome: A literature review, J. Pediatr. Urol., 17, pp. 246-254, (2021)
  35. Beaman G.M., Lopes F.M., Hofmann A., Et al., Expanding the HPSE2 genotypic spectrum in urofacial syndrome, a disease featuring a peripheral neuropathy of the urinary bladder, Front. Genet., 13, (2022)
  36. Nicanor F.A., Cook A., Pippi-Salle J.L., Early diagnosis of the urofacial syndrome is essential to prevent irreversible renal failure, Int. Braz. J. Urol., 31, pp. 477-481, (2005)
  37. Stamatiou K.N., Karakos C.D., Urofacial syndrome: A subset of neurogenic bladder dysfunction syndromes?, Indian J. Urol., 26, pp. 582-584, (2010)
  38. Leonard J.M., Central nervous system tuberculosis, Microbiol. Spectr., (2017)
  39. Gupta A., Garg R.K., Singh M.K., Et al., Bladder dysfunction and urodynamic study in tuberculous meningitis, J. Neurol. Sci., 327, pp. 46-54, (2013)
  40. Cherian A., Ajitha K.C., Iype T., Et al., Neurotuberculosis: an update, Acta Neurol. Belg., 121, pp. 11-21, (2021)
  41. Dian S., Ganiem A.R., van Laarhoven A., Central nervous system tuberculosis, Curr. Opin. Neurol., 34, pp. 396-402, (2021)
  42. McManus D.P., Dunne D.W., Sacko M., Et al., Schistosomiasis, Nat. Rev. Dis. Primers, 4, (2018)
  43. Lambertucci J.R., Silva L.C.D.S., do Amaral R.S., Guidelines for the diagnosis and treatment of schistosomal myeloradiculopathy, Rev. Soc. Bras. Med. Trop., 40, pp. 574-581, (2007)
  44. Bennett G., Provenzale J.M., Schistosomal myelitis: findings at MR imaging, Eur. J. Radiol., 27, pp. 268-270, (1998)
  45. Anon, Case records of the massachusetts general hospital. Weekly clinicopathological exercises. Case 4-1996. a 40-year-old woman with the rapid onset of flaccid paraplegia, N. Engl. J. Med., 334, pp. 382-389, (1996)
  46. Ferrari T.C.A., Moreira P.R.R., Cunha A.S., Spinal cord schistosomiasis: a prospective study of 63 cases emphasizing clinical and therapeutic aspects, J. Clin. Neurosci., 11, pp. 246-253, (2004)
  47. Gomes C.M., Trigo-Rocha F., Arap M.A., Et al., Schistosomal myelopathy: urologic manifestations and urodynamic findings, Urology, 59, pp. 195-200, (2002)
  48. Gomes C.M., Hisano M., Machado L.R., Et al., Urological manifestations of chronic schistosomal myeloradiculopathy, BJU Int., 96, pp. 853-856, (2005)
  49. Tiffreau V., Rapin A., Serafi R., Et al., Post-polio syndrome and rehabilitation, Ann. Phys. Rehabil. Med., 53, pp. 42-50, (2010)
  50. Cashman N.R., Raymond C.A., Medical news & perspectives, JAMA, 255, pp. 1397-1404, (1986)
  51. Farbu E., Rekand T., Gilhus N.E., Post-polio syndrome and total health status in a prospective hospital study, Eur. J. Neurol., 10, pp. 407-413, (2003)
  52. Ivanyi B., Nollet F., Redekop W.K., Et al., Late onset polio sequelae: disabilities and handicaps in a population-based cohort of the 1956 poliomyelitis outbreak in The Netherlands, Arch. Phys. Med. Rehabil., 80, pp. 687-690, (1999)
  53. Anon B., The Late Effects of Polio: Introduction To Clinical Practice, (2012)
  54. Johnson V.Y., Hubbard D., Vordermark J.S., Urologic manifestations of postpolio syndrome, J. Wound. Ostomy Cont. Nurs., 23, pp. 218-223, (1996)
  55. Kay L., Bertelsen M., Bladder symptoms among polio survivors, J. Rehabil. Med., 45, pp. 560-564, (2013)
  56. Anon, Overview: Post Polio Syndrome, (2022)
  57. Gilhus N.E., Myasthenia gravis, N. Engl. J. Med., 375, pp. 2570-2581, (2016)
  58. Tateno F., Sakakibara R., Aiba Y., Lower urinary tract symptoms in myasthenia gravis, Case Rep. Neurol., 13, pp. 490-498, (2021)
  59. Donskov A.O., Vinge L., Axelsen S.M., Et al., Overactive bladder in patients with myasthenia gravis-A cross-sectional population-based study, Acta Neurol. Scand., 144, pp. 76-80, (2021)
  60. Milhorat T.H., Classification of syringomyelia, Neurosurg. Focus, 8, (2000)
  61. Flint G., Syringomyelia: diagnosis and management, Pract. Neurol., 21, pp. 403-411, (2021)
  62. Vandertop W.P., Syringomyelia, Neuropediatrics, 45, pp. 3-9, (2014)
  63. Sakushima K., Tsuboi S., Yabe I., Et al., Nationwide survey on the epidemiology of syringomyelia in Japan, J. Neurol. Sci., 313, pp. 147-152, (2012)
  64. Brickell K.L., Anderson N.E., Charleston A.J., Et al., Ethnic differences in syringomyelia in New Zealand, J. Neurol. Neurosurg. Psychiatry, 77, pp. 989-991, (2006)
  65. Tsitouras V., Sgouros S., Syringomyelia and tethered cord in children, Childs Nerv. Syst., 29, pp. 1625-1634, (2013)
  66. Sakakibara R., Hattori T., Yasuda K., Et al., Micturitional disturbance in syringomyelia, J. Neurol. Sci., 143, pp. 100-106, (1996)
  67. Iaccarino C., Carretta A., Nicolosi F., Et al., Epidemiology of severe traumatic brain injury, J. Neurosurg. Sci., 62, pp. 535-541, (2018)
  68. Giacino J.T., Fins J.J., Laureys S., Et al., Disorders of consciousness after acquired brain injury: the state of the science, Nat. Rev. Neurol., 10, pp. 99-114, (2014)
  69. Cavanna A.E., Shah S., Eddy C.M., Et al., Consciousness: a neurological perspective, Behav. Neurol., 24, pp. 107-116, (2011)
  70. Eapen B.C., Georgekutty J., Subbarao B., Et al., Disorders of consciousness, Phys. Med. Rehabil. Clin. N. Am., 28, pp. 245-258, (2017)
  71. Laureys S., Owen A.M., Schiff N.D., Brain function in coma, vegetative state, and related disorders, Lancet Neurol., 3, pp. 537-546, (2004)
  72. Krimchansky B.Z., Sazbon L., Heller L., Et al., Bladder tone in patients in post-traumatic vegetative state, Brain Inj, 13, pp. 899-903, (1999)
  73. Giannantoni A., Silvestro D., Siracusano S., Et al., Urologic dysfunction and neurologic outcome in coma survivors after severe traumatic brain injury in the postacute and chronic phase, Arch. Phys. Med. Rehabil., 92, pp. 1134-1138, (2011)
  74. Cegielski J.P., Wallace R.J., Central nervous system infections with nontuberculous mycobacteria, Clin. Infect. Dis., 25, pp. 1496-1497, (1997)
  75. Christensen A.-S.H., Roed C., Oml L.H., Et al., Long-term mortality in patients with tuberculous meningitis: A danish nationwide cohort study, PLoS One, 6, (2011)
  76. Schaller M.A., Wicke F., Foerch C., Et al., Central nervous system tuberculosis: Etiology, clinical manifestations and neuroradiological features, Clin. Neuroradiol., 29, pp. 3-18, (2019)
  77. Ma Q., Ran H., Ou C., Et al., Is myasthenia gravis a contraindication for botulinum toxin?, J. Clin. Neurosci., 95, pp. 44-47, (2022)
  78. Wright I., Civitarese A., Baverstock R., The use of intra-detrusor onabotulinumtoxina in patients with myasthenia gravis, Can. Urol. Assoc. J., 10, pp. E184-E185, (2016)
  79. Jones S.C., Sorbello A., Boucher R.M., Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review, Drug Saf, 34, pp. 839-847, (2011)
  80. Takizawa T., Kojima M., Suzuki S., Et al., New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin, Medicine (Baltimore), 96, (2017)
  81. Khan Z., Bhola A., Urinary incontinence after transurethral resection of prostate in myasthenia gravis patients, Urology, 34, pp. 168-169, (1989)

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03